Healthcare technology, patient engagement and adherence : systems and business opportunity analysis by Jog, Chetan R. (Chetan Ravindra)
Healthcare Technology, Patient Engagement and Adherence:
Systems and Business Opportunity Analysis
By
Chetan R. Jog
B.E., Electronics Engineering, University of Pune, India, 1997
M.S., Computer and Systems Engineering, Rensselaer Polytechnic Institute, NY, 2000
Submitted to the System Design and Management Program
in Partial Fulfillment of the Requirements for the Degree of
ARCHNES
Master of Science in Management and Engineering
at the
Massachusetts Institute of Technology
June 2012
C 2012 Chetan R. Jog
All rights reserved
The author hereby grants to MIT permission to reproduce and to distribute publicly paper and electronic
copies of this thesis document in whole or in part in any medium now known or hereafter created.
Signature of Author _ _ _ _ _ _ R._Jog
Chetan R. Jog
System Design and Management Program
May 2012
Certified and Accepted by
Patrick Hale
Thesis Supervisor and Program Director
System Design and Management Program
Page Intentionally Blank
2
11 gft 11
ACKNOWLEDGMENTS
This presents a wonderful opportunity for me to express my sincere thanks to
those who were part of my journey, not only during completion of this thesis but
also while at MIT.
Firstly, I offer my deepest gratitude to my spiritual guru Sri Sri Ravi Shankar, for
giving me the right knowledge and strength to wade through the toughest of
circumstances and take bold decisions with a broad and deep understanding of
situations, life and existence.
My journey at MIT/Sloan School of Management begun with a clear objective
towards aligning my strengths, exploring my capabilities, expanding my circle of
rewarding relationships and most importantly gaining the tools to contribute as
much I can while I am around on this planet! Healthcare technology, I realized is
one of the several ways to achieve these objectives, by bringing my interest in
technology and the human aspect together.
The resources offered by the hands-on HST.921 course on health technology
innovation and commercialization, was a fantastic resource in engaging with the
leaders and pioneers such as Dr. John Halamka in this nascent industry. The
support and opportunity provided by Dr. Steven Locke to work on the business
case study at Veritas Health Solution was invaluable. Working with and leaming
the nuances of market research and financial modeling from the versatile Dr.
David Gruber was a truly rewarding experience. His down-to-earth willingness to
share his tacit knowledge as an executive in the corporate world and as a
physician made our several discussions truly pleasurable.
3
Pat Hale's attention to detail and patience was a key in keeping things stress-free
when I was meeting several deadlines. I am immensely thankful to Dr. David
Hartzband for helping me assimilate the intricacies of the US healthcare system
and in helping me decide on the area of this thesis. Also, I am thankful to the
help offered by friends, willing to lend their support at any time.
I express my heartfelt gratitude to my loving parents, reassuring sister and to my
ever-patient wife Prachi for their immense support at all levels.
4
TABLE OF CONTENTS
I MEDICATION ADHERENCE ANALYSIS .............................................................. 7
1.1 BACKGROUND AND RECENT TRENDS..................................................................... 7
1.2 REASONS FOR NON-ADHERENCE ........................................................................ 9
2 MEDICATION ADHERENCE AND DATA ANALYTICS: CURRENT TRENDS ...... 11
2.1 CURRENT ADHERENCE AND INCENTIVE SYSTEM SOLUTIONS............................... 11
2.2 STAKEHOLDER ANALYSIS .................................................................................. 12
2.3 MEASUREMENT OF ADHERENCE ........................................................................ 18
2.3.1 Issues in Measurement of MPR .............................................................. 19
2.4 THE R OLE OF DATA ........................................................................................... 20
2.4.1 Data Sources .......................................................................................... 21
2.4.2 Data Analysis, Knowledge Generation and Application .......................... 23
2.4.3 A commercial example of using data for medication adherence.............. 24
2.4.4 Analytics Using Consolidation of Electronic Health Record Data by Vendors
25
3 CURRENT AND FUTURE HEALTH TECHNOLOGY TOOLS AND PLATFORMS:
PATIENT ENGAGEMENT AND WELLNESS ............................................................ 27
3.1 STAKEHOLDER INCENTIVES ............................................................................. 27
3.1.1 Cost Reduction........................................................................................ 27
3.1.2 Health Engagement and Behavioral Change........................................... 28
3.1.3 Operational Efficiency ............................................................................... 28
3.1.4 Workforce Productivity Improvement ....................................................... 29
3.1.5 Patient Satisfaction ................................................................................ 29
3.2 C HANNELS ......................................................................................................... 30
3.2.1 Social - Wellness tools ............................................................................ 30
3.2.2 Patient Information Sharing Communities................................................ 33
3.2.3 Mobile Health Applications and Services ................................................ 34
4 TECHNOLOGY BASED INTERVENTION IN A BEHAVIORAL CARE PRODUCT: A
CASE STUDY ................................................................................................................. 38
4.1 IMPACT OF MENTAL HEALTH PROBLEMS ............................................................. 38
4.2 THE VERITAS SOLUTION ..................................................................................... 39
4.3 STAKEHOLDER ANALYSIS ................................................................................... 41
4.4 RELEVANT MARKET SEGMENTS......................................................................... 47
4.5 VALUE PROPOSITION......................................................................................... 49
4.6 COMMERCIALIZATION ANALYSIS FOR THE PRODUCT ........................................... 50
4.6.1 Determining the Economic Value to the Customer (EVC) ....................... 52
5 FUTURE POTENTIAL: ADOPTION, REGULATION AND BEYOND.................. 54
5.1 CONSUMER FOCUSED HEALTH INNOVATIONS AND THEIR ADOPTION DYNAMICS ..... 54
5.2 ADOPTION CONSIDERATIONS FOR MOBILE PLATFORMS ..................................... 57
5.3 ADOPTION FROM THE PROVIDER'S POINT OF VIEW............................................ 58
5.4 REGULATORY CONSIDERATIONS......................................................................... 59
5.5 VWiAT NEXT: FROM A BODY-MIND CENTRIC HEALTHCARE PERSPECTIVE TO
B EY O N D ? ..................................................................................................................... 62
6 REFERENCES ...................................................................................................... 63
5
Healthcare Technology, Patient Engagement and Adherence:
Systems and Business Opportunity Analysis
by
Chetan R. Jog
Submitted to the System Design and Management Program in May 2012
in Partial Fulfillment of the Requirements for the Degree of
Master of Science in Management and Engineering
Abstract
In the current shift in the US healthcare system, lower cost, higher quality of care,
access and safety are the main drivers that are effecting changes. Patient
compliance with medication and technology enabled wellness and engagement
programs play an important role in ensuring the cost and quality of care is
reduced. In a recent study, the overall cost of poor medication adherence,
measured in otherwise avoidable medical spending, is close to $310 billion
annually, representing approximately 14% of total healthcare expenditures.
There have been several studies analyzing the reasons for and impact of non-
adherence and solutions to achieve increasing compliance. With the recent wave
in healthcare technology, the scope of prescription medication adherence needs
to be expanded to include patient engagement and their awareness towards
lifestyle changes and managing their own health. This thesis engages in an
analysis of these compliance issues and in understanding the relationships
among the various stakeholders involved. It also analyses the several technology
platforms and solutions from mobile health to "gamification" and social networks
from a business, user and regulatory standpoint. It looks into how these newer
health technologies helps the individual in adhering and realizing novel insights
into their own patterns related to medication, lifestyle and general health. Further,
working with a health technology startup catering to the behavioral care market, a
real world application of a health technology product that utilizes technology
based patient assessment, decision support and patient communication, will be
evaluated to explore how it will help in delivering value to several stakeholders.
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I Medication Adherence Analysis
1.1 Background and recent trends
Low medication adherence has implications in several areas. Over 2000 years
ago Hippocrates warned physicians to "keep watch also on the faults of patients
which often make them lie about the taking of things prescribed". Today, within
the healthcare community, medication non-adherence is recognized with its
wider impact not only on the patient, but also on the multi-level systemic areas.
The New York Times calls non-compliance the world's "other drug problem".
Poor adherence is a striking global problem in healthcare. Several studies have
shown that global patient adherence rates, especially those suffering with chronic
conditions, average around 50% (WHO, 2003). In the US, a recent survey
(National Council on Patient Information and Education, 2007) showed that 49%
of respondents admitted to have forgotten a prescribed medicine, 31 % of
respondents had not filled a prescription they had been given, 29% of
respondents had stopped taking a medicine before the supply ran out and 24%
of respondents had taken less than the recommended dose.
The direct result of these challenging low adherence levels is a high cost of
healthcare and poor health care outcomes, as the first order effects. Figure 1
shows the cost of non-adherence to the US healthcare system. With a total cost
impact of more than 300 billion contributed mainly by hospital admissions.
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Patient non-adherence leads to significant costs for the healthcare system
Poor adherence leads to poor health outcomes and increased healthcare costs for
healthcare systems and authorities.
Research conducted by the New England Healthcare Institute (NEHI) in 2009
estimated that, in the US, the overall cost of poor adherence, measured in
otherwise avoidable medical spending, is close to $310 billion annually, representing
approximately 14% of total healthcare expenditures (Figure 3).
Figure 3: Cost of patient non-adherence to the US healthcare system
Cost of illnessfor drug non-adherence-related morbidity in US, 2008
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Figure 1: Cost of Patient non-adherence in the US
Source: Capgernini Consulting, "Patient Adherence: The Next Frontier in Patient Care", (Capgemini Consulting, 2009)
Non-adherence as such is complex and multidimensional issue with a very high
impact on the healthcare system in terms of health of individuals and the cost
burden on the already strained and complex healthcare system. To make matters
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even more serious, the number of stakeholders compounds the pathways to find
a solution to the problem.
1.2 Reasons for non-adherence
Factors non-adherence spans across finance, behavioral, social, health and
information domains. While the ranking of the reasons for non-adherence vary
according to several studies (AstraZeneca Study, 2008), the top four reasons
found are highlighted in Table 1. A combination of these reasons in practice
seems like the most likely cause for non-adherence.
Financial Behavioral Social Health Informational
Lack of Lack of
family/ disease or
social treatment
su port information
Cultural Low drug Lack of
satisfaction prescribed
drug
information
Poor
relationship
with self or
provider
Lack of
concern over
condition
Table 1: Adherence Cause Matrix
These reasons vary across socio-economic segments of society, age, condition,
provider-related and cultural factors. Interestingly, the importance attributed by
the various stakeholders with respect to the factors that drive adherence varies.
This is clear from Figure 2.
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Medication cost
Managed care
Pharma
Healthcare system and providers
Condition
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Fig 2: Ranking of factors driving adherence across stakeholders
Source: Capgemini Consulting, "Patient Adherence: The Next Frontier in Patient Care", (Capgemini Consulting, 2009)
While there is a definite trend among a targeted group of major stakeholders for
each of the factors, such as ranking Patient and Therapy related ones as those
driving adherence, Socio-economic factors is clearly one that payers rank much
higher than pharmacists or pharmaceutical companies. The probable reasons for
this may be availability of bulk data that drives the parameters of their insurance
plans, which are based on the correlation of affordability and demographics.
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2 Medication Adherence and Data Analytics: Current Trends
2.1 Current adherence and incentive system solutions
Since medication adherence is a multi-dimensional phenomenon, the mechanism
to tackle it needs a targeted approach, often evidence driven. Profiling patients
with high risk of non-adherence is a key measure that is beginning to get
employed with the availability of patient and prescription data.
Tables 2 and 3 show the several systems of adherence and incentive systems
that are implemented to help in compliance.
Medication Adherence Description Examples
System
Devices Devices used for helping adherence and to Senticare, Dose-alert,
track compliance McKesson - HealthBuddy
Software Services Software/mobile apps for reminders and Microsoft HealthVault
compliance tracking. CommunityConnect,
iGetBetter.com, Ginger.io
Education Doctor Education, Behavioral Health, PatientsLikeMe
Community Support
Reminders (Proactive Call from care team (provider, case mgmt., ScriptYourFuture Initiative
Intervention) home care etc.) to check and remind.
Studies show home delivery of medication
helps improve adherence by 15%.
Table 2: Medication Adherence Systems
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As we can notice, there are several adherence systems and in everyday
implementation a combination of these is most effective. A mobile application
that provides reminders and at the same time alerts the care team of anomalies
is one such example. In terms of incentive systems, these are essentially of only
two types: financial and behavioral/social. Financial ones are essentially driven
by payers and pharmaceutical companies, whereas the behavioral/social
applications and platforms are driven by payers that also include self-insured
employers. This is discussed in-depth in Section 3.2
Incentive System Description Examples
Financial Co-pay discounts, - McKesson Loyalty Script
(Co-pay discounts)
- Lottery
Behavioral/Social Gaming Social norming, gaming - Keas.com
HealthMedia.com
Table 3: Medication Adherence Incentive Systems
2.2 Stakeholder Analysis
Medication and wellness plan adherence is an issue that has multiple
stakeholders with complex relationships among them that comprise the fabric of
this system.
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The key stakeholders would generally include:
e Providers
This would include physicians, hospitals, nurses and other caregiving individuals
and institutions.
* Payers
Payers consists of public (federal government programs such as Medicare and
Medicaid, military insurance other state and local programs), private health
insurers and the largest component, employer funded insurance.
o Patients
For the purpose of our analysis, patients are all those who are under care of a
provider as well as those who are voluntarily engaged in wellness and lifestyle
programs and services.
s Pharmaceutical and Medical Device Companies
Prescription drug and medical device manufacturers licensed for use as
medications.
- Pharmacies
Entities that traditionally compound and dispense medication as well as involved
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in reviewing medications for safety and efficacy.
* Pharmacy Benefit Managers (PBM's)
Pharmacy Benefit Manager (PBM) is a third party administrator (TPA) of
prescription drug programs. They are primarily responsible for processing and
paying prescription drug claims. (Pharmacy Benefit Management, 2012)
- Government Health Agencies
These would generally include agencies that collect data, analyze it, devise
policies and programs, provide healthcare assistance in local settings (such as
community health centers)
e Third Party Healthcare Technology Service/Product Vendors
In the current upsurge in healthcare technology, this stakeholder would include
all those who provide technology based services and products towards collecting
data through software or devices, analyzing it, storing and delivering it to other
stakeholders. The primary service of these vendors include, presenting
meaningful insights from the data. Several health technology products including
Electronic Health Records, mobile applications, clinical decision support systems
are few examples.
- Hospital Patient Support
Case management staff in hospitals who are key individuals in transitioning care
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of patients in inter-provider and hospital to home settings. These become
important especially in patient communication and tracking adherence.
System Dynamics is a great methodology that will help us in analyzing these
relationships and how they affect each other. Also, it will allow us to predict the
dynamics of several players and unearth hidden insights from this complex
system. Fig 3 shows a representation of the system dynamics model using a
stock and flow causal diagram.
In simple terms, stock represents the state of any entity that accumulates or
depletes over time. The flow is the rate of change in a stock.
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Fig 3: Medication and Wellness Plan Adherence Dynamics
In Fig 3, we have two stocks, "Patients Adhering to Medication/Wellness Plan"
and "Pharma Co. Revenues"
Patients Adhering to Medication/Wellness Plan: This represents the number
of patients that comply either with prescription medicines or a wellness plan. A
prescription medicine is that prescribed by a healthcare provider for a time
period. Wellness plan as explained in section 3.2 is a plan that is either conveyed
by a healthcare provider, employer or is self-identified by the individual.
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Pharma Company Revenues: Revenues from pharmaceutical companies is a
direct function of the rate of adherence of patients to medication. This makes
them a major stakeholder in this system.
The recursive loop "Increased Patient Reporting" represents the relationship
between the number of individuals adhering to a prescribed regimen or those
using wellness plans, which is reflected in the variable, and their use of
technology services or products geared towards remote patient communication
and care. This in turn helps in increasing the adherence rate.
Increasing numbers of adhering patients also increases relevant data fed through
several sources represented by "Adherence Data". This data forms the
backbone of providing relevant incentives, education and other services to the
stakeholders as described in section 2.4. Increasing data helps in refinement and
innovation of these services based on analytics, which further help in increasing
the adherence rate. This forms the recursive feedback, which would help in
increasing patient adherence. An increase in the number of adhering patients
also would lead to better patient health outcomes, which lead up to another loop.
"Positive Health Outcomes" leads to increased productivity and cost
reductions for the several types of payers, which further incentivizes them to
support technology products, which increase the adherence rate, this forms the
"Payer Encouragement" recursive loop. Similarly payer incentives increase the
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use of patient communication technologies further helping cost reduction for
providers (such as due reduced staff requirement for billing and other patient
support) which induces providers to support patient engagement technologies.
This dynamic is indicated by the "Provider Push" recursive loop.
"Pharma Diminishing Returns" form the balancing loop, which is a result of
"Positive Health Outcomes". This would result in less patients needing any
prescription medications or compliance to any wellness plans. The combined
effect of decrease in the total patients under care, with the added effect of
increase adherence rates would result in a drop in drug sales. This would cause
less investment support by pharmaceutical companies towards adherence
services and products. Since pharmaceutical companies are a major
stakeholder, their support is critical. A drop in drug sales would lead them to re-
invest their resources away from adherence promotion to other avenues
expected to drive increasing company value.
2.3 Measurement of Adherence
While there are several ways to measure adherence, the Medication Possession
Ration (MPR) appears to be a popular metric. It is essentially the ratio of the total
days the member had drug available to the number of possible days the
participant could have drug on hand.
To illustrate the calculation of the MPR (Kevin T. Stroupe, Evgenia Y. Teal,
Wanzhu Tu, Michael Weiner, & Michael D. Murray, 2006), suppose a prescription
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was filled on September 30, with the next refill expected on October 30. If the
patient obtained the next (actual) refill on October 30, then the MPR would be 1.0
(30 expected days between refills divided by 30 actual days between refills),
indicating the new refill was obtained just as the patient ran out of drug. If the
patient instead received the next refill on October 15, then the MPR would be 2.0
(30 expected days divided by 15 actual days), indicating the patient obtained
twice the supply needed over that period. If the patient obtained the next refill on
November 29, then the MPR would be 0.5 (30 expected days divided by 60
actual days), indicating the patient obtained half the supply needed over that
period.
2.3.1 Issues in Measurement of MPR
Even as MPR may give an idea of the adherence levels of an individual, there
are certain issues in the methodological choices (Brenda Motheral) made in the
calculation of MPR. In the MPR formula, if the denominator is taken as the entire
period where the treatment discontinuation and gaps (time between depletion of
one claim and the refill) is taken into account the MPR tends to be lower, where
as if only the gaps are taken the MPR becomes higher.
Further, comparing MPR's can be illusive for two reasons:
1.) Comparing them between vendors who report it for different time periods
(multi-year versus quarterly) will give results that are related to the persistency of
medication (the duration of time from initiation to discontinuation of therapy)
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which is higher for shorter periods than longer.
2.) MPR is closely related to the whether the patient is new or ongoing. It has
been found the persistency is lower for newer patients compared to those who
are are being measured over a longer time. For a fixed time period this would
tend to lower the MPR for newer patients.
2.4 The Role of Data
As we have seen in the previous section tracking and measuring adherence
requires reliable data. The data can be gathered from a variety of sources
spanning the range of stakeholders. This data forms the gold mine of information
from which knowledge is gathered on demographic, health, lifestyle, adherence,
comparative effectiveness of drugs, efficacy of public health initiatives, early
warnings on epidemic outbreaks etc. Fig 4 provides and virtual architecture of the
sources of data and their uses.
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* Pharma
- Prescription
Fig 4: Health Technology Data Landscape
2.4.1 Data Sources
1.) Patient Reported and Device Gathered
This refers to the data gathered with an active input by a patient or a passive
one. An example of self-reported information could be that provided by entering
vital signs such as blood sugar level or pain level, miles walked and medication
taken into a web based service.
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With the increasing use of Near Field Communication (NFC) in mobile phones,
gathering health, behavioral and wellness data becomes close to being as non-
intrusive as possible for the subject.
The type and regularity of data obtained from patients is increasingly becoming a
new type of data source cable of giving information that was previously simply
unavailable for analysis. Further analysis of patient derived data is discussed in
section 3.2
2.) Electronic Health Record (EHR) and Hospital Data Warehouse Derived
EHR and data derived from Hospital information systems form a large part of
patient data. Aggregated data stored in a data warehouse (a database
specifically designed for efficient retrieval and analysis of data), implemented
increasingly by hospitals, form a data source that provides a more
comprehensive set of data.
3.) Prescription Related and Pharmaceutical Manufacturers
Data gathered from prescriptions form the most significant source for gathering
information specifically about compliance of prescribed medication. Pharmacies
and prescription networks are the best entities for gathering information on
prescriptions and trends. The information that is typically found would include,
among other demographics, age and prescription information.
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2.4.2 Data Analysis, Knowledge Generation and Application
Data analytics and, more so analytics of datasets that are orders of magnitude
larger than traditional ones (understood as "Big Data"), is becoming extremely
relevant in the healthcare context. Timely and synchronous analysis of these
voluminous datasets with a heterogeneous mix of structured and unstructured
data types (text, video, audio, log files etc.) can provide tremendous insights
which would otherwise remain hidden.
In the medication adherence context, this knowledge generation from the
combination of data does not limit one to adherence alone, but rather to a wealth
of insights for every stakeholder in the healthcare landscape. De-identified
patient data could be used for potentially unlimited applications, such as learning
about lifestyle, behavioral and social relationships, drug efficacy and comparative
effectiveness. The data also provides information that is relevant in the business
context for pharmacies, drug distributors and pharmaceutical manufacturers.
Identifying patients with high-risk of non-adherence, using the consolidated data
in predictive models has been found to be extremely useful in determining the
right incentives and communications increasing adherence. The correlation
among these applications and the knowledge they deliver make healthcare 'Big
Data' analytics the next frontier, with unlimited possibilities. Reducing healthcare
costs, increasing safety, spurring technology innovation, growing businesses and
learning about nuances in human behavior are some of the broad areas that
current and future efforts seem to be focused on.
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2.4.3 A commercial example of using data for medication adherence
In June 2011, the FICO* Medication Adherence Score was announced by FICO
(FICO Press Release, 2011), the company that measures credit with its
trademarked credit score. Instead of measuring how an individual borrows and
repays money, it measures how well a drug prescription is handled. The more
adherent an individual is to a prescription the higher will be their score. The score
is intended for providers, insurers and pharmaceutical companies to remind,
educate and provide incentives to persons with lower adherence.
For the creation of the proprietary scoring algorithm with a score that ranges from
1 to 500, FICO took data of several million de-identified patients provided by a
large pharmacy benefits manager (Simon). They observe the patients who filled
the prescription with those who didn't and identified the variables that best
predicted adherence. These variables include data such as age, family size,
assets, such data that are also used by marketing companies.
This commercial use of data for FICO scoring exemplifies the analysis in a
structured manner and the use of data for adherence, as well as measuring it for
use by the primary stakeholders to curtail costs. Pharmaceutical companies
clearly have higher revenue potential as a key benefit from knowing adherence
potentials of their drugs.
24
Applying the FICO score or other such metrics to measure prescription
medication adherence lead to several questions on how this information will be
used and shared. Privacy seems to be leading this list of concerns, with patients
not knowing with whom this data will be shared. A possibility could be, use by
payers who could discriminate against them for low scores in the future when the
FICO has been validated as an underwriting tool. Further, the combination of any
or all of the uncertainty in medical conditions, affordability of large medical
expenses and sudden change in one's economic condition can have a drastic
impact on the score. Compared to credit scores, where one can have disciplined
borrowing and debt repayment, commercialized adherence metrics may not take
into account contingent medical situations, which makes rectification of these
metrics challenging.
2.4.4 Analytics Using Consolidation of Electronic Health Record Data by
Vendors
EHR vendors, with a large market footprint, such as GE's Medical Quality
Improvement Consortium (MQIC) use the de-identified data from their installed
base of EHR's for analytics. Users of their EHR's who participate in the program
(nearly 20,000 providers) contribute to the approximately 20 million patient
records (GE MQIC). The benefits to the providers include comparative
performance against benchmarks for quality improvement. Quality reporting is
also done on behalf of the providers for pay-for-performance programs such as
the federal government's Patient Quaility Reporting System (PQRS). This
25
valuable database is also used for population research projects, reporting
epidemic outbreaks such as during H1 N1 influenza activity.
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3 Current and Future Health Technology Tools and Platforms:
Patient Engagement and Wellness
As we have seen in Table 1 prescription medication adherence systems include
Health IT systems that include standalone, Software-as-a-Service and mobile-
based solutions. These systems take us to the other side of adherence beyond a
typical view of prescription medication adherence towards adhering to lifestyle
and positive health choices.
3.1 Stakeholder Incentives
From this perspective, the incentives for the stakeholders are based on cost
reduction, health engagement and behavioral change, operational efficiency and
workforce productivity improvement factors.
3.1.1 Cost Reduction
The driver in reducing costs applies to several stakeholders but mainly to payers,
which could include private insurers and self-insured employers. Payers are
increasingly investing in programs that help participants in taking responsibility
for their health. The use of patient communication technologies, wellness tools
and self-diagnostic services are some of the leading methods being employed to
help participants achieve their health goals, which subsequently help in reducing
costs.
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3.1.2 Health Engagement and Behavioral Change
Public health agencies and non-profit organizations' use of technology solutions
for education contribute to achieving their health and wellness targets towards
improvement of their target population. These solutions include using several
communication channels including mobile text messages, emails, interactive
voice and mobile applications to educate individuals on specific health goals,
addiction cessation, making healthy lifestyle choices and also encouraging
medication compliance. A service such as Voxiva is an example of this type of
solution, which uses these communications channels for educating and
interacting with patients with diabetes, helping smoking cessation and for
maternal health. It also provides the data to health agencies to monitor and
derive insights from these programs.
3.1.3 Operational Efficiency
Health technologies and systems could offer a great solution in reducing the
burden that is placed on health providers due to a shortage in trained physicians
and facilities. We discuss, in a case study in Chapter 4, one such system that
uses a stepped care and patient communication model in the behavioral
healthcare space. This solutions aims to reduce the burden on psychiatrists by
referring only those patients who need urgent care to them and having others in
a graded model referred to nurse practitioners or through web or IVR telephone
support. These types of systems provide not only increase access to the most
needy patients but also reduce costs for the insurers as well as for the provider
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by optimizing their resources further with the use of patient communication
technologies.
3.1.4 Workforce Productivity Improvement
Employers use wellness programs to help reduce their health insurance costs.
Data shows that these programs are also of value when enhancing productivity is
taken into account. According to Dr. Pawel Suwinski, at Frost & Sullivan only
31 % of healthcare expenditure in organizations is spent on direct medical costs,
whilst 69% of medical costs are due to productivity loss. With the use of
technology solutions, employees' stress levels are managed and subsequently
any depression or co-morbid depression is also well managed. As is being
shown by studies (The HR Specialist: Compensation and Benefits, Oct 2008),
this not only helps in the maintenance of better employee health but also results
in overall productivity gains.
3.1.5 Patient Satisfaction
Patient portals are increasingly employed by physician practices as well as large
health systems to make it easier for patients to not only communicate better with
their care team but also make their visits into and out of the provider seamless.
Providing patients with forms or information before their visit, lab results,
reminders, detailed billing and after visit summary are some features that these
patient portal platforms offer. According to the 2011 Intuit Health survey "patients
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increasingly want online access for their healthcare information. 72 percent of
respondents between the ages 18-65 said they would use an online tool that
would help them communicate with their doctor more easily, make appointments,
get lab results and pay their medical bills." Patient portals are essentially multi-
sided technology platforms which are integrated with the providers systems such
as EHR's etc. and could be further enhanced by 3r party services such as
patient communities, SMS communication services and other relevant products.
Their use in ACO's makes their data integration capabilities much more relevant.
In all of these wellness based technology solutions, there are three themes that
dominate the patient communication aspect - Education, Incentives and
Engagement. How these are weaved together is discussed below through the
various channels.
3.2 Channels
The health technology systems that we discussed can have in general the
following three major delivery channels based on the stakeholder incentives and
the market segment.
3.2.1 Social - Wellness tools
These are tools that provide online platforms that engage, educate and provide a
forum for participants that encourage them towards their health goals.
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According to the 2011 Willis Health and Productivity Survey of employers, 60% of
respondents indicated they have some type of wellness program, an increase of
13% from 2010. Wellness programs are continuing to evolve, as more data on
efficacy is available and technologies channels such as mobile health and social
networks offer services that integrate participants' lifestyle with the engagement
and behavioral change goals of these platforms.
In general, wellness tools offer a lot of value to self-insured employers in terms of
reducing cost and improving productivity. From a higher-level perspective of the
healthcare system, corporations bear approximately 25% of the total nation's
health expenditures in the US.
There are several offerings by insurers as well as private enterprises that offer
wellness programs. An example of those offered by private players include
NumeralSocial and Keas. Participant engagement, incentives and education are
the key drivers as we mentioned before. NumeralSocial has innovated a
different model wherein they integrate the wellness program as an application
into the Facebook social network instead of a platform that has their own social
network. In the interview with their Vice-President of Product Management at
Numera Health, Bill Reid says the company's strategy is to integrate the
interaction of the participants within the program with the most prominent online
interactions. Use of targeted incentives increase wellness program participation
by 60%, according to the Incentive Research Foundation. The hypothesis is that
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a 'siloed' mobile application or internet platform affects the participation and
reduces the behavioral incentives offered by the limited social network offered in
such a system. With the popularity of Facebook, the company argues that
offering a application within it gives participants the best of the ability to choose
who they would want to collaborate and share with in a larger network as well as
integrate the platform in their daily outside-of-work lives. It is assumed that this
would help in increasing participation even more and offers greater choices on
who the participants would want to "compete" in online lifestyle games - using
"gamification" techniques. Companies that would want to exclude having their
wellness platforms as an application on Facebook for privacy reasons would
remain off-limits for such a model.
Gamification techniques offer participants incentives and empower individuals to
adopt and maintain health lifestyle habits. The company Keas offers programs
with gamified incentives. The program allows participants with an opt-in
competition software platform, where individuals or teams earn points by
completing lifestyle and health related tasks or challenges. Winners earn badges
and prizes, ranging from cash to gifts. Winners earn badges and prizes, ranging
from cash to gifts.
Game mechanics, social networking, rewards and team-based support provide
participants a great mix in reaching their health objectives in addition to being
entertaining. The health engagement provides employees with insights and
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comparison of their progress with the network. As a secondary effect it induces
the participants to learn more about their lifestyle choices and adjust them for
better outcomes.
3.2.2 Patient Information Sharing Communities
These are online platforms that do much like the social-wellness but for the
business model and the emphasis on sharing information about the members'
medical conditions, side effects and being a resource for medical knowledge.
These platforms are essentially driven by members who main incentive is to
share their knowledge and experience and the same time learn from other
members' experiences. Patientslikeme, founded by MIT graduate Heywood
brothers and a company which is at the forefront of these community platforms
also have members who could sign up for clinical trials based on their conditions.
Their business model is based on sharing member data with the several
stakeholders in the healthcare fabric.
The wealth of data that is shared by individuals in such communities offers a
perspective that hitherto was simply not available. This includes clinical and
lifestyle related data. For example a lot of knowledge could be gathered on how
patients use drugs, when they stop, their side effects and could be used to draw
correlations. These observational trials give a totally different aspect as to how
intervention works in the real world by including those patients who otherwise
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would have been eliminated from structured clinical trials, which may not reflect
the actual patient profiles.
The possible challenge in these platforms could be maintaining the incentives for
users to participate regularly and sign-in into their condition tracking programs,
as well as reaching out to larger spectrum participants such as those similar in
age and other demographics.
3.2.3 Mobile Health Applications and Services
Mobile health or 'mHealth' as it is popularly known is increasingly becoming a
significant integrator of the several offerings and channels of patient
communication, engagement, education and data gathering.
According to the Consumer Health Information Corporation (CHIC) survey
(mobihealthnews, 2011) 91.1% of survey respondents said they wanted an app
that provided them with health information, while 58.4 percent would like to
manage a health issue via mobile. 48.5% said they wanted to track their own
health. About 79% said they would they would be more motivated to use an
app that analyzed their data and provided feedback. While tracking data might be
exciting, a large portion of survey takers wanted apps to find information on
drugs (42%) or disease (26.5%). About 40% of survey respondents would use a
health app multiple times a day.
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It is becoming increasingly clear that with the increasing adoption of smartphones
(about 50%), according to Nielsen Mobile Insights 2012, a 14 percent point
increase from the year before, the use of healthcare related mobile apps signals
a shift in the way individuals consume and share information in the patient-
provider-payer setting as well with others in a social network.
Fig 5 provides a high level perspective of the mobile health landscape.
Essentially, as we see in Table 4, mHealth apps and services fall into four major
categories.
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mHealth App/Service Description and Examples
Application that range from provider communication and alerts, such
Patient as something in the patient report to appointment billing and billing.
Communication
Wellness related applications reflect the need to track lifestyle habits
Wellness and modify them through insights and incentives. Typical application
involve those related fitness, sleep and nutrition tracking and stress.
From a patient care, medication adherence and care plan tracking
perspective, data availability carries prime importance. mHealth
applications that use diagnostic devices that could be connected to
Data Collection smartphones or those that use Near Field Communication or user
provided data such as adherence are some examples. The analytics
performed on such data increases the value of these apps to the users
provides an incentive for greater participation.
Health information is one of the top most searches on the internet.
Behavioral, Availability of such data on a smartphone & sharing it in a social
Informational and network provide behavioral incentives. A good example would be
Educational programs such as smoking cessation, which provide timed personal
challenges that could be shared among the users' network.
Table 4: Mobile Health Application/Services - High Level View
The relevance of all of these channels to medication compliance or a wellness
program is connected by the ability of all of them to track patient behavior.
Accessing patient medication patterns at a more granular level, as well as
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encouraging the participants of these programs through behavioral incentives in
a social network, provides promise for increasing their adherence levels.
Mobile Healh
# Patient n 
Wellness 
Ai k aa Gathering Bhvoa
Meication
Fig 5: Mobile Health Landscape
From the perspective of other stakeholders, these technologies provide
healthcare providers and researchers access to such data and at such a scale
simply not previously available to them. Redirecting these insights back to the
patients help them in making positive lifestyle choices
At least 50% of medical costs are preventable by lifestyle adjustments, and 75%
of all medical costs caused by chronic diseases are best prevented and treated
by lifestyle adjustments (Frost & Sullivan, 2010). These cost advantages, in tur,
help the payers, providers and government health agencies in reaching their
financial or policy metrics.
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4 Technology Based Intervention in a Behavioral Care Product:
A Case Study
Several studies (Kessler D, 2009) (King VL, 2009) have shown the remarkable
efficacy of computer based remote mental health therapy over that in regular
primary care. Veritas' solution provides a practical application of a technology-
based solution using Cognitive Behavioral Therapy, invented by a group of
experts including psychiatrists, technologists and business strategists at Veritas
Health Solutions (Veritas).
The main concept of this solution revolves around technology-supported selfcare
in the behavioral health care space and includes the following:
Real-time measurement of status, risk assessment and feedback
Automated stepped care (resource matching)
- Tailored therapy
Among the other benefits to the target user and buyer, this solution would help in
clinical decision support, keeping communication with patients and help them in
adhering to medications and care plans.
4.1 Impact of Mental Health Problems
Mental health problems are common, under-recognized, under-treated and
costly. Among the several effects of this, it leads to:
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e High resource utilization due to the multiple undiagnosed physical
symptoms which confound medical diagnosis
e Poor medication adherence and general low interventions to treat this
e Loss of employee productivity
- Increased risk of substance abuse
- Lifestyle risks (such as sedentary behavior, poor nutrition and obesity)
4.2 The Veritas Solution
Fig 6 gives a high-level design of the solution. To understand the application of
this system in a real world setting, let us take the example of a patient who feels
she is depressed and engages this system. A sample flow will look something
like this:
1. She will enroll and provide her symptoms or conditions using Interactive
Voice Response or web-based interview conducted by a trained professional for
gathering data for her condition assessment.
2. The responses provided by her will be fed into a multi-source database
that integrates data from multiple sources related to her. For example, it could
include a provider database on her prescriptions, adherence, and symptom
monitoring. In large hospitals, a data-warehouse could be linked.
3. This aggregated data is then given to the Resource Intensity Treatment
Adjustor (RITAP), which is the proprietary algorithm that determines the level of
care that is most appropriate for the patient.
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4. The decision point here is whether she needs a behavioral health referral
or not. If she does, the level of care is determined, for urgent care (example: high
suicide risk) a psychiatrist would be alerted and for non-urgent care a nurse
practitioner. If she does not need referral, the technology supported self-care
model will assist her.
The solution spreads the demand on providers across several levels in terms of
the type of care provider as well as the type of care required. At a high level, this
directly helps in reducing the burden on the provider and increases access to
patients as well reduces cost for the payer due to reduced reimbursement ratesa
for treatments that are not given by the psychiatrist.
Mddmindb-
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Fig 6: Technology Architecture of the Veritas Solution
Source: Veritas Health Solutions (Steve Locke, 2011)
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4.3 Stakeholder Analysis
From a business perspective, the applicability of these solutions relates to
several stakeholders in healthcare, with providers, payers and patients being the
most closely related ones. A comprehensive stakeholder analysis was done by
Veritas to identify and lay out the value proposition for each of them. This was an
initial step to further analyze and point out who the primary stakeholders would
be and move towards finalizing the target market segments for commercialization
of the solution.
As we see in Table 5, the number of stakeholders is large. From a strategic
standpoint the applications of the solution for a stakeholder or a set of
stakeholders would make the most sense where there is a large untapped
market and where go-to-market strategies are readily implementable. Towards
these objectives, preliminary analyses revealed two possible applications of the
technology as discussed below.
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Stakeholder Value Proposition
Military/Veterans Health
Self-insured Employers
Improves patient outcomes and satisfaction, better ability
track patients, cost, personalized, improves quality, oper.
Productivity gains and cost reduction. Remote patient
Table 5: Veritas Stakeholder Analysis
1. Co-Morbid Depression
This term refers to the depression that occurs in the presence of physical illness,
usually of a chronic nature. Features of depression typically include (Jones,
2012):
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- sleep disturbance;
- loss of interest in everyday things such as hobbies and family;
- inability to look forward to things;
- loss of self esteem; and
- change in appetite.
People who have conditions that produce a lot of pain, restriction of activity or a
poor outlook are all prone to developing depression on top of their existing
illness. This depression then tends to further exacerbate the chronic conditions,
such as asthma, diabetes or congestive heart failure (CHF).
Fig 7 shows a significant increase in the costs per member per month (PMPM)
of various chronic conditions for an individual with depression.
$3,000
$2,500
$2,000
$1.500
* No Depression
$1,000 I Depression
$500
$0
Diabetes Asthma COPD Cancer Chronic Stroke CHF
pain
Fig 7: Comparison of medical costs PMPM for co-morbid depression
Source: Milliman Research Report. Chronic conditions and co-morbid psychological disorders, July 2008.
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The higher cost of treating patients with co-morbid depression is particularly
impacting payers (such as self-insured employers and health insurance
companies, as well as Medicaid and Medicare) in terms of their overall increase
in costs.
From the perspective of employers, employees with co-morbid depression or
those with other stress-induced anxiety often develop more severe physical
manifestations. This phenomenon is known as somatization; a natural mind/body
process in which emotional distress manifests as physical symptoms (e.g.,
blushing, palpitations, chest pain).
The combination of co-morbid depression and somatization leads to significant
impact on productivity in terms of increased abseentism, presenteeism (which is
the tendency to over-work when sick, leading to less productivity) and overall
sub-standard quality of the work delivered. Fig 8 dearly shows the significance of
the the costs associated due to depression in the workforce and the related costs
that an employer would have to bear in terms of reduced productivity and in
higher medical insurance costs for a self-insured employer'.
1 Self-insured employers are those who bear the burden of medical insurance for their employees by risk pooling.
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Economic Burden of Depression, 2000
$83.1 Billion
Suicide
Related Costs
Presenteeism
Absenteeism
Inpatient Care
Outpatient Care
Pharmaceutical
Costs
Inflation adjusted burden
of $106.6 b in 2010
annual inflation of 2.5%
during this period
51
Fig 8: Economic Burden of Depression
Source: Greenberg PE, et al. J Clin Psychiatry. 2004;64:12.
2. Adolescent Depression and Student Mental Health
Demand for mental health services in colleges is rapidly rising. A recent survey
by American College Health Association (ACHA) shows 25% of the 11 million
students in 4-year institutions in the US are affected by mental health conditions.
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Students affected with behavioral health issues
Impacted Populations
On campus suicides:
>1,100 students
,* ,~ *,
8**
There are 11.0 million students in 2,500 4-
year institutions within the U.S.
Fig 9: Number of students affected with behavioral health issues in the US
Source: ACHA National College Health Assessment, 2010
Such an unprecedented rise in the number of students seeking counseling or
other treatment also impacts the demand on the student health centers. In the
National College Health Assessment of 2008, 30% of college students
considered "seeking help from a professional if they were having problems that
really bothered them." This proportion of students seeking help results in
overwhelming the mental health services at educational institutions. Fig 10
shows the tilting of the balance of demand and supply in the student health
system.
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Fig 10: Demand and supply imbalance - student health services at educational institutions
This imbalance is created mostly by the budget restrictions, the rising number of
students that are seeking services and the complexity of the cases that leads to
additional interventions.
4.4 Relevant Market Segments
Considering the target applications the most valuable market segments were
determined to be integrated healthcare networks (IHN) and student health -
educational institutions. In this case study we are focusing on IHN's.
Integrated Healthcare Networks (IHN)
IHN's are a managed care system in the United States that includes a hospital
organization that provides acute patient care, a multispecialty medical care
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complexity
f psychiatrists,
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delivery system, the capability of contracting for any other needed services, and
a payer (Medical Dictionary). Geisinger Health System in Pennsylvania or the
Henry Ford Health System in Michigan are some examples of major and well
known IHN's.
Geoffrey Moore evolved Everett Roger's diffusion of innovations theory to
expound more on the granularity of technology adoption in his book "Crossing
the Chasm". He categorized the adoption cycle into five segments. As we see in
Fig 8, the chasm accordingly exists between the early adopters of technology
and the early majority pragmatists and for a new technology commercialization is
the greatest challenge. If we map IHN's and self-insured employers into this
model, we see that they are spread across the first three segments of this
adoption cycle. There are those such as Children's Hospital Boston or Kaiser
Permanente are using and innovating path breaking health technologies for
providers and patients in several areas. At the same time there are others who
have just adopted or those who have opened up towards adapting or enhancing
current innovations to their needs. The trend among IHN's and self insured
employers is clearly towards crossing this chasm with the use of technologies
that support their cost reduction goals. Care models such as Patient Centered
Medical Homes (PCMH) and Accountable Care Organizations (ACO) whose
targets are to reduce healthcare costs with better collaboration between the
member organizations dictate that technologies are used for goals that include
patient communication, decision support, clinical and financial data analytics.
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These models, in spite of their challenges in finding greater acceptance are
paving the way for providers to adopt technologies that reduce cost, increase
access, quality and safety, as well providing better patient satisfaction.
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Fig 11: Crossing the chasm
4.5 Value Proposition
IHN's typically serve as providers, payers and self-insured employers. The value
proposition from them from Veritas' solution is relevant for all three aspects of
their identity.
The scale of patients served, the willingness of these IHN's to integrate health
technology systems offer them significant cost and operational benefits as payers
and providers. In addition, the ability to maximize the ROI for Veritas were the
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primary factors that led to making IHN's the key market segment for the go-to-
market strategy.
Veritas' system of technology based patient assessment, clinical decision
support and patient communication using a stepped care serves model reduces
cost and increase operational efficiencies for the IHN's.
4.6 Commercialization Analysis for the Product
Fig 12: Flow of Money in the Health IT Landscape
Source: Zen Chu, MIT Entrepreneurship Center (Chu)
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Bringing the product to market and devising the go-to-market process in an
environment with multiple stakeholders is much streamlined once the flow of
money is investigated. Fig 12 shows this flow in Health IT. For Veritas, the
eventual beneficiaries as buyers are payers (private insurance companies, self-
insured employers) and providers. As users the beneficiaries are patients and
providers. From a go-to-market standpoint the following decision making strategy
was generally applied:
1.) Payers and providers that are technology conscious, and
2.) Whose needs match Veritas' value proposition closely and who could
derive maximum benefit from the product.
3.) Customers who represent a large market. This would be an efficient
method for Veritas to reach their volume and future profitability targets
A thorough financial analysis was done, which consisted of determining the
market size of patients with co-morbid depression, and scoping it to those who fit
the following filter
1.) Insured
2.) Adults (> 25 years old)
3.) Fall into these market segments:
a.) Patients with 2+ chronic conditions AND mood disorders, depression plus
anxiety OR anxiety alone
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b.) Patients with primary mood disorders, depression + anxiety OR anxiety alone
c.) Chronic pain (migraines or low back pain)
After taking into account realistic figures, that included factors such as patients
refusing treatment and patients not detected by screening, an addressable
market of about 62 million patients was realized.
Once an addressable market was known, a few sample case studies with IHC's
made it possible to create the revenue forecast. To make this estimation the
pricing structure included software licensing, implementation, customer support
and maintenance charges.
4.6.1 Determining the Economic Value to the Customer (EVC)
This was an essential step towards finding the right price point/s and for creating
a coherent marketing pitch for the customer.
In order to calculate the EVC, the key was to calculate the cost avoidance with
Veritas' system as compared to what they were presently incurring. To do this
the cost avoidance was calculated for each of the three market segments.
The total cost avoidance for each segment involved determining the a.) cost of
Veritas' product - b.) cost avoidance attributed to the use of the product.
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For determining b.) the number of patients that would be would be given care by
physician (MD's) versus those given by others in the trained clinical staff for
behavioral therapy (such as PhD or Master trained nurses or assistants) and
through technology assisted therapy was multiplied with the reimbursement
rates for each type. This was then compared to the current proportion of care
given by MD's and other clinical staff.
Since the reimbursement rate for MD's is higher than the other clinical staff and
acknowledging the fact that a higher proportion of insured's would get moved to
non-MD's owing to Veritas' stepped care model, there is a clearly realizable cost
benefit for the IHC's. The EVC was instrumental in showcasing the value of the
product.
In the final profitability analysis spanning five years, a practicable adoption rate
within the addressable market taking in conjunction with the pricing and cost for
Veritas showed a profitable business opportunity in this time span. Growth
estimates year-to-year assumed growth in the number of patients cared for per
customer plus the growth in the number of customers added.
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5 Future Potential: Adoption, Regulation and Beyond
With the explosion of healthcare technological solutions and companies, there is
an expansion in offerings and entrepreneurial activity. It is hard not to draw
parallels between the explosion of the auto industry in the US, in the later part of
the 19t century when they were about 2000 firms to the 3 major ones in span of
the next 40 years. The health technology industry is bound to see consolidation
in the number of players as well as integration in the channels of communication,
means of data generation and analysis as well that for providing coordinated
care.
5.1 Consumer Focused Health Innovations and Their Adoption Dynamics
Tracking prescription medication adherence, knowing the reasons, and
encouraging increased patient compliance through creative incentives is now
closely tied to the latest health technology innovations and care models.
The shift from an enterprise centric, health focused mindset to a consumer
focused, lifestyle and wellness centric one will make a big difference in how
patient care is managed. That said, from a consumer or patient perspective the
experience for them is most valuable and hassle-free when their interactions with
the technology systems are well integrated with their lifestyle goals, their
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communications with the provider, and the insights they want to gain from their
activities, be they related to medication or lifestyle.
Such seamless integrated solutions give added value when their data can easily
be shared from one provider to the other or from one technology platform to
another. With the market opportunity for such systems abound, we are still in the
early but exciting stage of healthcare technology innovation, in which we have
adopters who come by choice and those are pulled into it. Fig 10 shows an
overview of the market reality with how a user type fits with the scale of adoption
of health technology.
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explorers" are the ones who would be or are the early adopters and are, in one
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way, the marketers of such technologies. That said, it is the other two "Involved
Without Choice and "Enthusiasts Nudged by the System" who make up the bulk
of the adopters. From a perspective of disruption, "Self-knowledge enthusiasts"
are the one whose advocacy and passion will make the providers and payers to
take a hard look into changing their care and reimbursement models that will
jumpstart these newer innovations in health technology.
From a consumer perspective then, it is very important to see who adopts these
systems and why, at the same time estimating how it would help change the
current effort in tackling the healthcare cost, access, safety and quality related
issues.
Let us take the example of "Quantified Self' (QS); a movement to incorporate
technology to acquire data about an individual's daily activities, such as sleep,
food, mood, environment etc. Their initiative started with the aim to have "a
collaboration of users and tool makers who share(d) an interest in self knowledge
through self-tracking". QS users are signed-up to the basis that this data
gathering is done with simple non-intrusive methods, such as through sensors,
devices and mobile applications. The users main interest is to be able to look at
data in ways that provides them self-discovery insights that are novel. At the
same time they also want to know what to do to influence their measurements
and scores. An example of this would be the Basis heart rate monitor that is
embedded in a watch. It offers analytical tools that motivate users to make
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changes when required, such as a possible heart rate increase at a stoplight that
causes road rage. Although QS provides great user value, it is still at the leading
edge of healthcare innovation on the consumer side, with adopters who fall into a
very narrow market segment. There are several such innovations on the patient
engagement side in which the main driver of adoption is the consumers' own
motivation for self-improvement. While there are others such as NumeralSocial
that we discussed in section 3.2.1 where social network and gamification is used,
their adoption is driven by clear incentives and encouragement by those who
have clear stake in seeing increased adoption, such as self-insured employers
who aim to reduce cost.
5.2 Adoption Considerations for Mobile Platforms
The increasing adoption of smartphones and tablets, their ubiquity and value
they provide to the user makes mobile healthcare applications one of the
dominant modes for achieving the objectives of the stakeholders. But this also
brings about the issue of relevance and participation rates. The actual value
proposition and utilization depend a lot on the market segments that these are
applicable to.
According to a study done by Chilmark Research (Moore, 2012) that in the
market, mHealth application developers struggle to sign on users, especially
those that have chronic conditions, to consistently use their application. It
mentions that whenever it has become successful, it has been due to the
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continuous feedback received by the users from the clinical side. The success of
a mobile application then rests partly on who deploys the application.
Also, some other examples of applicability would include those where mHealth
apps designed for smartphones may not be able to track patient information for
seniors as well have them communicate with their providers due to the lesser
adoption of smartphones in this segment. Tablets apps such as those for iPads
may be more suitable for them. In the case of drawing insights from prescription
drug use among demographics with very limited use of Internet, technology
solutions or simple feature-phone SMS would provide means of communication.
Also, having a Facebook application for wellness program may not be suitable for
the older generation of employees who may not be able to draw upon the
advantage it offers of a larger network due to generational preferences.
5.3 Adoption From the Provider's Point of View
In any health technology adoption from a providers point of view, when they are
tight on schedules and set with their workflow, any new addition of tool(s) is not
considered without a proper value proposition with its quantified efficacy and also
the possibilities for reimbursement. When the current reimbursement models do
not quite support things such as patient communication using mobile
applications, it creates a situation where innovations and entrepreneurial activity
in this area is looked at with a lot of suspicion by investors and could lead to
lesser commercialization of innovations. The possible way out this is the payment
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model: one from a fee for service delivered in a hospital or clinical setting to that
which is based value-based outcomes where the patient is an active contributor
in their own care.
In either case, careful consideration ought to be given to the choices made in
deciding the platform, channel or technology used to cater to the diversity in the
market. A combination of these may prove to be a solution although its
practicability is eventually decided by the speed and scale of benefits for the
stakeholders involved.
5.4 Regulatory Considerations
Since the healthcare technology that includes software and devices at the
meeting point of providing care, diagnosis and the patient, federal regulation,
especially by the US Food and Drug Administration (FDA), becomes a very
important factor in bringing the innovations into the market with due consideration
given to patient safety.
Since the traditional technology industry is regulated primarily by the standards
set by industry consortia, where they compete based on these standards and
their strategies, the entry of novel technologies or patient procedures into the
healthcare space is faced by a mindset clash. This is because the responsibility
of their products and services on the wellbeing of the individuals they are
intended to serve is not observed when they - for example - market a product
that facilitates data collaboration in the cloud. This can be perceived as a burden
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when commercializing health technology products, which, based on market
analysis, exhibit tremendous business opportunity but have regulation barriers
that are not expected in the hi-tech industry.
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Fig 11: Innovation vs Regulation Forces
Source: MobiHealthNews (Thompson, 2012)
The FDA could regulate within its mission to protect safety of individuals and at
the same time encourage innovation to promote overall public health. From an
entrepreneurial standpoint, the passion of bettering public health, gaining insights
and realizing market opportunity could be stymied by overbearing regulation. The
regulation is not only a clearance to market (pre-market clearance) the products
but also how they are marketed and advertised. Here, established companies
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who have systems in place and experience in bringing health technology
products to the market gain an upper hand.
Fig 11 gives a graphical representation of these seemingly opposing interests
between the freedom to innovate and FDA mission to protect against adverse
events. The ideal position would be at the top right comer of this chart. There are
essentially four force that are guiding where existing federal regulation are
placed. Congress and the FDA are essentially the primary forces that steer the
point. This point may change with greater acceptance and proven outcomes and
safety of the products regulated, as well as well as the competitive nature of the
players within this industry.
The range of health technologies and the media used, from mobile Health to
home diagnostic devices (some of them interfaced with a mobile device) and
their interconnectedness with enterprise HIT systems makes regulation of these
systems complex. For example, take the case of when a blood glucose meter is
connected to a cell phone that is then connected to a server and a PC in the
doctor's office. When something goes wrong and an erroneous result is
displayed on the doctor's monitor, it is difficult to point out clearly which
component manufacturer has the post-market obligations to report the so-called
adverse event to the FDA (Thompson, 2012). There need to be clear guidelines
to figure out who and how to investigate and point out the responsible entities.
All in all, it is a great learning process for the players - the regulators, industry,
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and product users - as to how to navigate this space of seeming conflict. The
best possible way of out of this would be high-level collaboration among these
players. Industry bodies such as mHealth Regulatory Coalition that provide
consensus and a single voice to the FDA are examples of this collaboration.
Greater participation by the consumers and investors in this consensus building
and working with the regulators will only make the process easier. Learning from
past experiences of new product ecosystems and how they were efficiently
regulated (such as green products by the Environmental Protection Agency) as
well from how health technology is regulated around the world seem promising
ways of making regulation in healthcare technology reach the golden point.
5.5 What Next: From a Body Centric Healthcare Perspective to Beyond?
The focus here was on the healthcare technologies and patient engagement
primarily in the US. It is clear that people are becoming more aware about their
health and well-being. Yoga and meditation was not in the mainstream 30-40
years ago, but as things evolve, people are becoming increasingly conscious
about their lifestyle choices. The combination of this technology-enabled trend
and of an environment where payers, providers, pharmaceutical companies and
healthcare innovators want this health-aware mindset for increasing their value,
is overall a very good situation for the individual. It allows the individual to explore
the depths of their being from a body centric one to one that involves the mind,
intellect, memory, ego and consciousness complex and realize greater truths of
human existence.
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